SEC Form 4 · accession 0001209191-15-045620
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
L Daniel Browne
Officer — CEO and President · Director
Period of report
May 19, 2015
Accepted (ET)
May 21, 2015 · 6:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 19, 2015 | F | 12,025 | $25.94 | D | 205,101 | D | |
| Common StockF2 | holding | — | — | — | 269 | D | ||
| Common StockF3 | holding | — | — | — | 409 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares withheld by and surrendered to the Issuer on May 19, 2015, to satisfy tax withholding obligations that arose in connection with the vesting of the Restricted Stock Award ("RSA") for 96,000 shares. The RSA vests in three equal annual installments from May 19, 2014, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
- F2These shares were acquired by the Reporting Person under the Issuer 2014 Employee Stock Purchase Plan on December 31, 2014.
- F3These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.